EVFM
Evofem Biosciences Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Evofem Biosciences, Inc., is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women.
Market Cap: 114 Million
Primary Exchange: NASDAQ
Website: www.evofem.com
Shares Outstanding: 182 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.0516669974995638
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2625 trading days
From: 2018-01-02 To: 2022-08-10
Lowest Point:
Daily Insider Ratings Round Up 6/10/19
via: SeekingAlpha at 2019-06-12 08:44:01:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 6/10/19
via: SeekingAlpha at 2019-06-12 08:44:01:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Evofem Biosciences Closes $80 Million Financing Transaction with PDL BioPharma and Other Long-time Investors
via: PR Newswire at 2019-06-10 12:01:00:000
SAN DIEGO and INCLINE VILLAGE, Nev. , June 10, 2019 /PRNewswire/ --Evofem Biosciences, Inc. (NASDAQ: EVFM) (Evofem), a clinical-stage biopharmaceutical company, and PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today announced the closing of the second tranche for $50 million of an a… read more...
Evofem Biosciences Closes $80 Million Financing Transaction with PDL BioPharma and Other Long-time Investors
via: PR Newswire at 2019-06-10 12:01:00:000
SAN DIEGO and INCLINE VILLAGE, Nev. , June 10, 2019 /PRNewswire/ --Evofem Biosciences, Inc. (NASDAQ: EVFM) (Evofem), a clinical-stage biopharmaceutical company, and PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today announced the closing of the second tranche for $50 million of an a… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2018-01-18 | 6.0 | 1.0 | 6.0 |